drugset / Trial / NCT01852058
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Non-randomizedParallel-groupQuadruple-blindTreatment
Summary
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully completed Study 191622-120 (NCT01852045).
Timeline
- Start
- 2014-01-11
- Primary completion
- 2018-11-22
- Completion
- 2019-10-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 50 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 100 iu | Intramuscular |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 200 iu | Intramuscular |
Indications
No indication recorded.